We propose that OCTA may serve as a more sensitive modality to assess the efficacy of mTOR inhibitors for TSC-associated RAHs, considering that blood flow is essential for tumor growth and that changes in RPC or SCP vascular density may precede the changes in maximal thickness of RAHs. This evidence concerns the gene TSC1 and neoplasm.